Название продукции:ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate
IUPAC Name:ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate
- CAS：1224944-77-7
- Молекулярная формула：C9H8ClN3O2
- Чистота：95%+
- Номер в каталоге：CM103556
- Молекулярная масса：225.63
Только для использования в НИОКР..
Информация о продукции
- Номер CAS:1224944-77-7
- Молекулярная формула:C9H8ClN3O2
- Точка плавления:-
- Smiles-код:CCOC(=O)C1=C2N=C(Cl)C=CN2N=C1
- Плотность:
- Номер в каталоге:CM103556
- Молекулярная масса:225.63
- Точка кипения:
- Номер Mdl:MFCD12407819
- Хранение:Keep in a tight container and store at ambient temperature，protect from light，apparatus for firefighting
Category Infos
- Pyrazolopyrimidines
- Pyrazolopyrimidine scaffolds are one of the most important heterocyclic compounds in drug discovery. This scaffold has various biological activities, among which anticancer is an important one.
Column Infos
- KT-474
- Kymera announced that the first patient has been dosed in the randomized Phase 2 clinical trial in hidradenitis suppurativa (HS) evaluating KT-474 (SAR444656). The Phase 2 study will evaluate the efficacy, safety, pharmacokinetics, and biological effects of KT-474 compared with placebo in adult patients with moderate to severe HS. Kymera's partner Sanofi is conducting the Phase 2 study in HS, and has initiated a second randomized Phase 2 trial in AD. Under the terms of the collaboration, dosing of the first patient in the HS trial generated a milestone payment of $40 million. KT-474 is an oral IRAK4 degrader, in development for the treatment of IL-1R/TLR-driven complex inflammatory diseases where there is an opportunity to significantly advance the standard of care, including HS and AD. Sanofi, which is collaborating with Kymera on the development of KT-474 outside of the oncology and immune-oncology fields, is conducting the Phase 2 studies.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
- Repotrectinib
- Repotrectinib receives approval for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) from the U.S. FDA on November 15, 2023. ROS1 gene is altered in about 1-2% of patients with NSCLC. ROS1-positive lung cancer tends to be aggressive and can spread to the brain and the bones.
Repotrectinib is a highly potent and differentiated small molecule TKI that binds inside the ATP pocket, and is active against both wild-type and resistant mutations, including solvent front and gatekeeper mutations. Repotrectinib is expected to enter the U.S. market in mid-December 2023.
Поиск 
+86 21 5895 0110 
